What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Another Take on the 2022 EULAR RA Treatment Guidelines
Dr. Peter Nash reviews the new 2022 EULAR RA Treatment Guidelines, presented at #EULAR2022.
Watch video →
EULAR 2022 - Day 2 Faculty Recap Panel
Dr. Jack Cush, Dr. Robert Chao and Dr. Richard Conway discuss interesting abstracts and seminars from day 2 at EULAR 2022.
Watch video →
2022 ASAS/EULAR Recommendations on the Management of Axial Spondyloarthritis
Dr. Peter Nash discusses the new ASAS/EULAR Spondyloarthritis treatment guidelines presented at EULAR 2022
Watch video →
RA Potpourri on Day One EULAR 2022: Not An Ugly Duckling
Dr. Jonathan Kay reports on RA-related sessions and abstracts from day 1 at EULAR 2022.
Watch video →
New 2022 ASAS/EULAR Recommendations on the Management of AxSpA
Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force.
Watch video →
EULAR 2022 - Day 1 Faculty Recap Panel
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at EULAR 2022 - Guidelines, Lupus, and more.
Watch video →
Dr. John Cush RheumNow
3 years 2 months ago
Have you registered for RheumNow yet? With registration you'll be able to sign up for our daily email, as well as our topic specific emails.
RheumNow is where rheumatologists come to learn.
https://t.co/NuN8JL37tk https://t.co/urJGorSzxo
Dr. John Cush RheumNow
3 years 2 months ago
Prevalent Sleep Problems in Rheumatoid Arthritis
Data from Data FORWARD (The National Databank for Rheumatic Diseases) reveals that nearly two-thirds of rheumatoid arthritis (RA) patients have self-reported sleep problems.
https://t.co/WHv3BBeI8T https://t.co/awSy2VqBIn
Dr. John Cush RheumNow
3 years 2 months ago
Disease Activity Scoring in AOSD
AOSD or sJIA can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed upon.
https://t.co/oD6uDD6W8m https://t.co/KxNJeJ31h8
Dr. John Cush RheumNow
3 years 2 months ago
ANA Increasing? Part of the NHANES survey, ANA (IIF on HEp-2 cells) was performed on 13,519 in 3 periods: 1988-1991, 1999-2004, and 2011-2012. ANA+ was
11% 1988-1991
11.4% 1999-2004
16.1% 2011-2012 (P <0.0001)
Meaning ~22.3, ~26.6, &~41.5 mil had +ANAs https://t.co/vWYJci3uDV https://t.co/SEIbrYRoRJ
Dr. John Cush RheumNow
3 years 2 months ago
SURPRISED? Psoriasis pts have a known increased risk of CV disease. But did you know several papers & metanalyses show increased risk of abdominal aortic aneurysm in PSO (HR 1.30), worse w/ dz activity; lost w/ age, female, DM? https://t.co/UssLZsBJle https://t.co/ESGK8fjjJk https://t.co/CBBYZRCjCA
Benjamin Terrier TerrierBen
3 years 2 months ago
Anti-PM-Scl connective tissue diseases - By Paul Breillat (Fellow in Internal Medicine, Paris, France) #connective #scleroderma #myositis #PMScl #InternistAcademy https://t.co/P727E4ddzz
Laurent ARNAUD Lupusreference
3 years 2 months ago
✅ Probably one of my most important slides ⬇️
WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Eric Topol EricTopol
3 years 2 months ago
This precipitous drop and current level is substantially worse than 21 peer countries
https://t.co/NAEMjhs4j3 https://t.co/QhrZ1Xnwcr
Ian N Bruce Lupusdoc
3 years 2 months ago
In a nutshell, reducing glucocorticoids in #SLE patients is associated with a number of important clinical benefits and may impact risk of other comorbidities such as BP and infection risk. https://t.co/YBoIU6aK8p
STAT statnews
3 years 2 months ago
Life expectancy for Americans is the lowest it's been since 1996. Read about the decline from @sheridan_kate https://t.co/QwkOmOt2Tp https://t.co/wavGjOv6q5
Today the FDA authorized the updated Omicron subvariant (BA.4 and BA.5) COVID-19 booster shots manufactured by Pfizer and Moderna; with an anticipated ship/start date of early September 2022. The BA.5 subvariant accounts for more than 88% of U.S. infections.
Dr. John Cush RheumNow
3 years 2 months ago
Statin Myalgias? Lancet metanalysis of 19 PCTs, >80K pts, @ 1yr, Statin caused a 7% increase in muscle pain or weakness (1·07; 1·04–1·10); thus 1 in 15 had myalgia due to statin (1/10 w/ high dose). After year 1, no signif excess in statin related myalgia https://t.co/6cRJQMymzM https://t.co/RTH56J4FD1
NICE (UK) has systematically reviewed current medical evidence and delivered a set of recommendations with consideration of cost effectiveness.
Dr. John Cush RheumNow
3 years 2 months ago
After historic drop in 2020 (COVID), life expectancy in USA dropped again, this time a full year to 76.1 years. The lowest since 1996 and the biggest 2-year decline in a century (dropping >2.5 yrs). To date, there have been 1,044,937 COVID deaths in USA https://t.co/aSgtw6MvGs https://t.co/0UKeyGujKe
Dr. John Cush RheumNow
3 years 2 months ago
Tapering biologics in Still's/Systemic JIA? 4 studies suggests after sustained inactive disease achieved, options include QOD (anakinra) dosing or dose reduction or interval prolongation (CAN & TCZ). KEY: early biologic starts https://t.co/33tjr65Gi0 https://t.co/fi6fc4NPgG
Poster Hall